Literature DB >> 3691581

Pharmacokinetics of cefotaxime and its desacetyl metabolite in plasma and in cerebrospinal fluid.

E Beyssac1, J M Cardot, G Colnet, J Sirot, J M Aiache.   

Abstract

The aim of the study was to investigate the pharmacokinetic modelling of Cefotaxime (CTX) and its main metabolite Desacetyl Cefotaxime (DCTX) which has a less antibacterial activity than the CTX. After intravenous administration of 1g of CTX to 26 patients, the plasma concentrations determined by HPLC showed that the pharmacokinetics of CTX and transformation to DCTX can be described with an open five-compartment model. The implications of this are discussed from the clinical point of view.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3691581     DOI： 10.1007/BF03189882

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


  12 in total

Review 1.  The penetration of antibiotics into cerebrospinal fluid and brain tissue.

Authors:  R W Barling; J B Selkon
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

2.  Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?

Authors:  J T Noble; M Barza
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 3.  Pharmacokinetics of the new cephalosporins.

Authors:  J M Brogard; F Comte
Journal:  Antibiot Chemother (1971)       Date:  1982

4.  Human metabolism of cefotaxime.

Authors:  D S Reeves; L O White; H A Holt; D Bahari; M J Bywater; R P Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.

Authors:  R M Ings; D S Reeves; L O White; R P Bax; M J Bywater; H A Holt
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

6.  [Technic for assaying cefotaxime and desacetylcefotaxime in serum by high performance liquid chromatography].

Authors:  M Boyer; J Sirot; R Cluzel
Journal:  Pathol Biol (Paris)       Date:  1984-04

7.  Cefotaxime in treatment of meningitis and ventriculitis? Evaluation of drug concentrations in human cerebrospinal fluid.

Authors:  O Brückner; H Collmann; H G Hoffmann
Journal:  Intensive Care Med       Date:  1982-01       Impact factor: 17.440

8.  Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.

Authors:  H C Albin; F M Demotes-Mainard; J L Bouchet; G A Vincon; C Martin-Dupont
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

10.  Cefotaxime levels in ventricular cerebrospinal fluid, determined by bioassay and by high-performance liquid chromatography.

Authors:  O Brückner; H Collmann; K Borner
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544
View more
  3 in total

1.  Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man.

Authors:  R Nau; G Zysk; A Thiel; H W Prange
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 3.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.